Unlocking the Potential of Cell and Gene Medicine in Asia-Pacific

The Asia-Pacific (APAC) region is emerging as a significant hub for the burgeoning field of cell and gene medicine development.

Life Sciences Review | Tuesday, May 20, 2025

The Asia-Pacific (APAC) region is emerging as a significant hub for the burgeoning field of cell and gene medicine development. Fueled by increasing healthcare expenditure, a large patient pool with unmet medical needs, supportive regulatory landscapes, and growing research capabilities, the industry in this region is experiencing robust growth and innovation.

A Flourishing Ecosystem

The development of cell and gene therapies in APAC is underpinned by a dynamic ecosystem involving academic research institutions, biotechnology firms, and contract development and manufacturing organizations (CDMOs), and evolving regulatory frameworks. Governments across the region are increasingly recognizing the transformative potential of these advanced therapies, a potential that is driving policies to accelerate their development and accessibility. This includes streamlining regulatory pathways, providing research grants, and fostering collaborations between academia and industry.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Academic institutions in APAC are at the forefront of basic and translational cell and gene therapy research. Their groundbreaking discoveries lay the groundwork for novel therapeutic approaches targeting various diseases. Furthermore, the increasing number of biotechnology companies dedicated to cell and gene medicine is translating this research into clinical applications. These companies are actively engaged in preclinical studies, clinical trials, and the development of scalable manufacturing processes.

The growth of the cell and gene therapy sector has also spurred the establishment and expansion of CDMOs within APAC. Often unsung heroes, these organizations provide crucial support in process development, manufacturing, and quality control, enabling therapy developers to focus on their core research and clinical activities. The availability of robust manufacturing infrastructure, primarily due to the efforts of CDMOs, is critical for the successful translation of cell and gene therapies from the laboratory to patients.

Key Areas of Development

Among the most active areas is CAR T-cell therapy, a form of immunotherapy that reprograms a patient’s T cells to target and eliminate cancer cells. In APAC, research efforts are intensifying to enhance the safety and efficacy of CAR T-cell therapies, particularly for hematological malignancies, while extending their application to solid tumors. This includes advancements in CAR design, antigen targeting, and methods to counteract the immunosuppressive tumor microenvironment.

Gene therapy is another rapidly evolving domain, with both in vivo and ex vivo modalities under development. These therapies aim to correct or replace faulty genes to treat or prevent diseases, with notable progress in addressing genetic disorders such as inherited retinal diseases, hemophilia, and spinal muscular atrophy. Researchers across the region are also exploring gene therapy solutions for acquired conditions. Critical to these advancements are innovations in viral and non-viral delivery vectors, which are essential to improving therapeutic safety and efficacy.

In parallel, cell-based therapies utilizing mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and natural killer (NK) cells are gaining momentum. These therapies are being evaluated for a range of indications, including autoimmune diseases, cardiovascular disorders, and neurodegenerative conditions. Scientific efforts are centered on elucidating the mechanisms of action, enhancing therapeutic potency, and developing scalable, reproducible manufacturing and delivery platforms.

Genome editing technologies, such as CRISPR-Cas9, are transforming the capabilities of cell and gene therapies in the region. These tools offer unprecedented precision in modifying genetic material, enabling targeted correction of mutations and engineering cells with enhanced therapeutic functions. APAC-based researchers are at the forefront of applying genome editing to develop novel treatments for genetic disorders, cancers, and infectious diseases, reinforcing the region’s growing prominence in the global biotechnology landscape.

The regulatory landscape for cell and gene therapies in APAC is evolving, with many countries adapting their frameworks to accommodate the unique characteristics of these advanced medicinal products. Regulatory agencies are working towards establishing clear guidelines for preclinical testing, clinical trials, manufacturing, and post-market surveillance to ensure the safety and efficacy of these therapies while facilitating their timely access to patients. Harmonization of regulatory requirements across the region remains an ongoing effort to streamline the development process for therapies intended for multiple markets within APAC.

Manufacturing and Infrastructure

Cell and gene therapies present unique complexities due to their autologous or allogeneic nature and the need for stringent quality control. Developing robust and scalable manufacturing processes is crucial for ensuring the availability and affordability of these therapies. APAC is witnessing significant investments in building advanced manufacturing facilities, including those adhering to Good Manufacturing Practices (GMP) standards. Furthermore, innovations in manufacturing technologies, such as closed systems and automation, are being explored to enhance efficiency and reduce costs.

Cell and gene medicine development in APAC holds immense promise for the future. Continued advancements in basic research and technological innovations in gene editing, cell engineering, and manufacturing will pave the way for developing novel and more effective therapies for a broader range of diseases. Increased collaboration between academia, industry, and regulatory agencies will be crucial for accelerating the translation of scientific discoveries into clinical practice. Furthermore, addressing challenges related to cost and accessibility will be essential to ensure that these transformative therapies reach the patients who need them most across the diverse populations of the APAC region. The ongoing momentum in this field, which should inspire our audience, suggests that APAC will continue significantly contributing to the global landscape of cell and gene medicine, bringing hope and innovative solutions to patients facing debilitating diseases.

More in News

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Inventus welcomes senior figure from Google as a board adviser

Autologous and Allogeneic Models Push Cell Therapy Toward Different Development Paths

Cell therapy product development is becoming more segmented as autologous and allogeneic products place different demands on design, manufacturing and commercialization. Developers can no longer discuss the sector as one uniform category. Product strategy depends heavily on whether cells come from the patient or from a donor source. Autologous therapies are often built around individualized production. A patient’s own cells are collected, processed and returned as a therapy. This model can create a strong biological fit, but it also places pressure on scheduling, chain of identity, release timelines and site coordination. Every patient-specific batch becomes both a treatment and a manufacturing event. Allogeneic therapies take a different approach. Instead of using each patient's own cells, they rely on donor-derived or engineered cells that can be produced in larger batches and supplied to more patients. This model has the potential to improve access and make therapies more widely available, provided quality, immune compatibility and long-term performance are carefully managed. At the same time, it brings its own set of challenges, including how cells are sourced, how consistently they can be expanded during manufacturing, how they are stored and how different patients may respond to the treatment. Industry analysis from Thermo Fisher Scientific’s Patheon unit notes that autologous therapies require individualized handling because each treatment is tailored to a patient’s cells, while allogeneic therapies must ensure consistent quality and address immune compatibility across recipients. These differences influence product development from the very beginning. For autologous therapies, developers often concentrate on coordinating the entire vein-to-vein process, including logistics, site readiness, rapid release testing and making sure each patient's cells move through the system efficiently. Developers of allogeneic therapies face a different set of priorities, with greater attention on master cell banks, consistency between production batches, inventory management and large-scale quality control. Each approach comes with its own operational challenges, costs and risks that need to be managed throughout development. Manufacturing partners are therefore becoming more specialized. A partner supporting allogeneic production may need scale-up expertise and robust batch release processes. Developers must choose partners based on model fit, not general cell therapy experience alone. Digital systems are becoming important in both pathways. Developers need data continuity from cell collection through manufacturing and administration. Gaps in records can create delays and weaken confidence. Better data handling can support quality review and long-term learning across batches or patient cases. The future of cell therapy product development will likely involve both models advancing in parallel. Autologous and allogeneic approaches solve different problems and face different barriers. The companies best positioned will be those that align biology, manufacturing design, clinical planning and commercial delivery around the specific therapy model they are building. ...Read more

Specials

Unlocking the Potential of Cell and Gene Medicine in Asia-Pacific

The Asia-Pacific (APAC) region is emerging as a significant hub for the burgeoning field of cell and gene medicine development.